Tasly Pharmaceutical Group Co., Ltd (SHA:600535)
China
· Delayed Price · Currency is CNY 14.64
-0.28 (-1.88%)
Feb 28, 2025, 3:00 PM CST
SHA:600535 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Net Income | 859.06 | 1,071 | -264.24 | 2,359 | 1,126 | Upgrade
|
| Depreciation & Amortization | 496.2 | 493 | 517.95 | 487.77 | 539.67 | Upgrade
|
| Other Amortization | 6.3 | 23.14 | 14.73 | 15.23 | 50.36 | Upgrade
|
| Loss (Gain) From Sale of Assets | -2.11 | -0.15 | -1.48 | -44.22 | -1.73 | Upgrade
|
| Asset Writedown & Restructuring Costs | 364.5 | 1.78 | 352.26 | 265.48 | 66.41 | Upgrade
|
| Loss (Gain) From Sale of Investments | 69.45 | 270.75 | 1,158 | -1,682 | -355.07 | Upgrade
|
| Provision & Write-off of Bad Debts | - | 8.19 | -1.34 | -5.35 | 65.46 | Upgrade
|
| Other Operating Activities | 5.92 | -2.03 | -31.24 | 123.82 | 254.5 | Upgrade
|
| Change in Accounts Receivable | 78.22 | 1,243 | 535.51 | 1,231 | -397.93 | Upgrade
|
| Change in Inventory | 18.32 | -220.72 | -2.86 | -198.37 | 56.58 | Upgrade
|
| Change in Accounts Payable | 121.58 | -395.35 | 36.56 | 243.78 | 324.51 | Upgrade
|
| Change in Other Net Operating Assets | - | 67.76 | 11.01 | 3.44 | 15.17 | Upgrade
|
| Operating Cash Flow | 2,015 | 2,576 | 2,280 | 2,801 | 1,791 | Upgrade
|
| Operating Cash Flow Growth | -21.78% | 12.98% | -18.62% | 56.39% | 6.61% | Upgrade
|
| Capital Expenditures | -564.94 | -668.82 | -404.41 | -571.73 | -408.81 | Upgrade
|
| Sale of Property, Plant & Equipment | 27.58 | 1.19 | 1.34 | 68.92 | 6.3 | Upgrade
|
| Cash Acquisitions | - | - | - | -147.31 | - | Upgrade
|
| Divestitures | - | - | - | 424.19 | 734.01 | Upgrade
|
| Investment in Securities | -287.57 | -134.14 | -919.91 | 126.42 | 39.33 | Upgrade
|
| Other Investing Activities | -115.94 | -1,307 | 56.75 | 56.76 | 89.9 | Upgrade
|
| Investing Cash Flow | -940.87 | -2,109 | -1,266 | -42.83 | 865.86 | Upgrade
|
| Short-Term Debt Issued | - | 213.91 | 102.79 | 1 | 57.3 | Upgrade
|
| Long-Term Debt Issued | 1,451 | 1,817 | 2,711 | 1,441 | 4,937 | Upgrade
|
| Total Debt Issued | 1,451 | 2,031 | 2,814 | 1,442 | 4,994 | Upgrade
|
| Short-Term Debt Repaid | - | -127 | -9.87 | -82.14 | -82.72 | Upgrade
|
| Long-Term Debt Repaid | -2,511 | -1,345 | -2,311 | -2,717 | -6,308 | Upgrade
|
| Total Debt Repaid | -2,511 | -1,472 | -2,321 | -2,799 | -6,391 | Upgrade
|
| Net Debt Issued (Repaid) | -1,059 | 559.55 | 492.71 | -1,358 | -1,397 | Upgrade
|
| Repurchase of Common Stock | - | - | -60.8 | -56.43 | -94.76 | Upgrade
|
| Common Dividends Paid | -1,042 | -563.22 | -553.97 | -610.49 | -799.29 | Upgrade
|
| Other Financing Activities | -352.18 | -1,193 | -114.58 | -458.73 | -20.12 | Upgrade
|
| Financing Cash Flow | -2,454 | -1,196 | -236.63 | -2,483 | -2,311 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.16 | -1.26 | 30.39 | 1.94 | -12.15 | Upgrade
|
| Net Cash Flow | -1,380 | -730.54 | 807.36 | 276.97 | 334.16 | Upgrade
|
| Free Cash Flow | 1,450 | 1,907 | 1,875 | 2,229 | 1,382 | Upgrade
|
| Free Cash Flow Growth | -23.98% | 1.68% | -15.89% | 61.28% | 45.61% | Upgrade
|
| Free Cash Flow Margin | 17.06% | 21.98% | 21.71% | 28.04% | 10.18% | Upgrade
|
| Free Cash Flow Per Share | 0.97 | 1.28 | 1.28 | 1.48 | 0.92 | Upgrade
|
| Cash Interest Paid | - | - | 4.05 | - | 0.2 | Upgrade
|
| Cash Income Tax Paid | 993.38 | 1,099 | 1,106 | 1,008 | 1,112 | Upgrade
|
| Levered Free Cash Flow | 1,042 | 1,348 | 1,517 | 2,531 | 5,668 | Upgrade
|
| Unlevered Free Cash Flow | 1,042 | 1,399 | 1,557 | 2,580 | 5,847 | Upgrade
|
| Change in Net Working Capital | -170.52 | -652.27 | -591.03 | -1,872 | -4,798 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.